Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival

• Published in: Genome medicine 2018-12, Vol.10 (1), p.94-94, Article 94
• Main Authors: Tang, Wei, Zhou, Ming, Dorsey, Tiffany H, Prieto, DaRue A, Wang, Xin W, Ruppin, Eytan, Veenstra, Timothy D, Ambs, Stefan
• Format: Article
• Language: English
• Subjects: Bioinformatics; Biology; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Chromatography; Chromatography, Liquid; Consortia; Female; Gene expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic aspects; Genomes; Humans; Liquid chromatography; Mass Spectrometry; Mass spectroscopy; Medical prognosis; Messenger RNA; Metabolic pathways; Myc protein; Oligonucleotide Array Sequence Analysis; Patients; Protein expression; Protein synthesis; Proteins; Proteomes; Proteomics; Scientific imaging; Signal Transduction; Software; Survival; Systems analysis; Transcription; Transcription (Genetics); Tumors
• ISSN: 1756-994X; 1756-994X
• DOI: 10.1186/s13073-018-0602-x

Transcriptome analysis of breast cancer discovered distinct disease subtypes of clinical significance. However, it remains a challenge to define disease biology solely based on gene expression because tumor biology is often the result of protein function. Here, we measured global proteome and transcriptome expression in human breast tumors and adjacent non-cancerous tissue and performed an integrated proteotranscriptomic analysis. We applied a quantitative liquid chromatography/mass spectrometry-based proteome analysis using an untargeted approach and analyzed protein extracts from 65 breast tumors and 53 adjacent non-cancerous tissues. Additional gene expression data from Affymetrix Gene Chip Human Gene ST Arrays were available for 59 tumors and 38 non-cancerous tissues in our study. We then applied an integrated analysis of the proteomic and transcriptomic data to examine relationships between them, disease characteristics, and patient survival. Findings were validated in a second dataset using proteome and transcriptome data from "The Cancer Genome Atlas" and the Clinical Proteomic Tumor Analysis Consortium. We found that the proteome describes differences between cancerous and non-cancerous tissues that are not revealed by the transcriptome. The proteome, but not the transcriptome, revealed an activation of infection-related signal pathways in basal-like and triple-negative tumors. We also observed that proteins rather than mRNAs are increased in tumors and show that this observation could be related to shortening of the 3' untranslated region of mRNAs in tumors. The integrated analysis of the two technologies further revealed a global increase in protein-mRNA concordance in tumors. Highly correlated protein-gene pairs were enriched in protein processing and disease metabolic pathways. The increased concordance between transcript and protein levels was additionally associated with aggressive disease, including basal-like/triple-negative tumors, and decreased patient survival. We also uncovered a strong positive association between protein-mRNA concordance and proliferation of tumors. Finally, we observed that protein expression profiles co-segregate with a Myc activation signature and separate breast tumors into two subgroups with different survival outcomes. Our study provides new insights into the relationship between protein and mRNA expression in breast cancer and shows that an integrated analysis of the proteome and transcriptome has the potential